Since the levels of phosphorylated ERK1/2 and p38 MAPK in asthmatic cases correlate to the severity of airway disease (57, 58), inhibition of MAPK signal pathways was suggested as a new strategy for the treatment of airway inflammation and asthma (50, 59, 60). Here, MAPK3 is linked to asthma.